Article · 13 Feb 2026
Conference abstractPublished 21 Oct 2013
RFID technology and regulations for pharmaceuticals
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Radio frequency identification (RFID) is one of the key enabler technologies which can facilitate item level serialization in the pharmaceutical supply chain especially for track-n-trace and e-pedigree applications. However, challenges exist at both regulatory and technical levels before a wide scale adoption is possible throughout the industry. In this presentation, we will provide an overview of the RFID technology, current regulations with respect to its use in the pharmaceutical supply chain, and discuss some of the limitations specifically concerning biologics. Per compliance policy guide CPG Sec.400.210, radiofrequency identification feasibility studies and pilot programs for drugs, the U.S. Food and drug administration (FDA) has excluded drugs covered under a biologics license application or protein drugs covered by a new drug application from being used in RFID pilots due to the fact that the impact of radio frequency waves on proteins is not extensively documented. We will discuss a recent research study which investigated the non-thermal effects of radio frequency waves on different biopharmaceuticals such as hormones, vaccines and immunoglobulins. Five frequencies (13.56 MHz, 433 MHz, 868 MHz, 915 MHz, and 2.4 GHz) were used to represent the most commonly used international frequency bands for RFID applications. For testing, to simulate a worst case scenario, the products were exposed to magnetic and electromagnetic fields with power levels beyond Federal communications commission (FCC) regulated commercial limits for a full 24 hour period. The in vitro test results on different biopharmaceuticals from eight major companies showed no non-thermal effect by radio frequency waves.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ismail Uysal”

